In a significant advancement for digital health, the Saudi Food and Drug Authority (SFDA) has granted marketing authorization for an innovative AI-powered medical application that measures vital signs such as heart rate, oxygen saturation, and blood pressure using smartphone cameras. This approval marks the SFDA as the first regulatory body in the world to authorize such an application, following a rigorous evaluation of its safety and performance based on technical documentation and clinical evidence. The application employs remote photoplethysmography (rPPG) technology, which leverages sophisticated algorithms to analyze vital signs from a brief facial video. To ensure the accuracy of its readings, the app necessitates an initial calibration of blood pressure with a certified medical device and is not designed for emergency or critical care scenarios.
The launch of this application is the result of a collaborative effort between the SFDA and the Ministry of Health, represented by the Seha Virtual Hospital. Developed by a specialized Canadian firm, the application underwent extensive testing within the SFDA's Regulatory Sandbox before progressing through the authority's Innovative Medical Devices pathway, fulfilling all evaluation criteria, including a dedicated clinical trial conducted in Saudi Arabia. This initiative reflects the SFDA's dedication to fostering digital health innovation and ensuring the secure introduction of cutting-edge technologies into the Saudi market.
This milestone not only highlights the SFDA's commitment to embracing advanced technological solutions but also aligns with the objectives of the Health Sector Transformation Program, a cornerstone of Saudi Vision 2030. As the country gears up for the Year of Artificial Intelligence in 2026, this approval underscores the SFDA's ongoing efforts to promote modern medical technologies and enhance the healthcare landscape in Saudi Arabia.
The launch of this application is the result of a collaborative effort between the SFDA and the Ministry of Health, represented by the Seha Virtual Hospital. Developed by a specialized Canadian firm, the application underwent extensive testing within the SFDA's Regulatory Sandbox before progressing through the authority's Innovative Medical Devices pathway, fulfilling all evaluation criteria, including a dedicated clinical trial conducted in Saudi Arabia. This initiative reflects the SFDA's dedication to fostering digital health innovation and ensuring the secure introduction of cutting-edge technologies into the Saudi market.
This milestone not only highlights the SFDA's commitment to embracing advanced technological solutions but also aligns with the objectives of the Health Sector Transformation Program, a cornerstone of Saudi Vision 2030. As the country gears up for the Year of Artificial Intelligence in 2026, this approval underscores the SFDA's ongoing efforts to promote modern medical technologies and enhance the healthcare landscape in Saudi Arabia.
Source: Saudi Gazette
